SAB BiotherapeuticsSABS
SABS
About: SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Employees: 63
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 25 [Q4 2024] → 26 (+1) [Q1 2025]
4.59% less ownership
Funds ownership: 28.53% [Q4 2024] → 23.94% (-4.59%) [Q1 2025]
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
70% less capital invested
Capital invested by funds: $10.1M [Q4 2024] → $2.99M (-$7.12M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
251%
upside
Avg. target
$12
602%
upside
High target
$20
1,070%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Keay Nakae | 1,070%upside $20 | Buy Maintained | 15 May 2025 |
HC Wainwright & Co. Emily Bodnar | 485%upside $10 | Buy Assumed | 14 May 2025 |
HC Wainwright & Co. Edward White | 251%upside $6 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or delay the progression of type 1 diabetes.
Neutral
GlobeNewsWire
2 months ago
SAB BIO Reports Full Year 2024 Operating and Financial Results
MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the fourth quarter of 2024 in addition to its full year financial results for the fiscal year ended December 31, 2024, and reported on recent accomplishments and anticipated milestones. Samuel J. Reich, Chairman and CEO of SAB BIO stated, “Our recent announcement of positive topline data for SAB-142, further strengthens our belief that SAB-142 has the potential to be the best in-class disease-modifying therapy for T1D.
Neutral
GlobeNewsWire
4 months ago
SAB BIO to Participate in Upcoming Investor Conferences
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti-thymocyte immunoglobulin (hIgG) that potentially delays the onset or progression of type 1 diabetes (T1D), today announced that members of its management team will participate in the following investor conferences:
Negative
Benzinga
4 months ago
Why Is SAB BIO Stock Trading Lower On Tuesday?
On Tuesday, SAB BIO SABS released topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers.
Neutral
GlobeNewsWire
4 months ago
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that SAB-142 is well-positioned for re-dosing in outpatient setting for type 1 diabetes Results will be presented in an R&D webinar event today at 8:00 am ET; registration details below MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers. The study met its primary objectives related to safety and pharmacodynamic activity enabling SAB-142 to advance to Phase 2b clinical development.
Neutral
GlobeNewsWire
4 months ago
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO's management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and Silverstein Family Eminent Scholar Chair in Pediatric Endocrinology.
Neutral
GlobeNewsWire
7 months ago
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year.
Neutral
Accesswire
8 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into SAB Biotherapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / October 3, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
8 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / September 30, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
8 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherapeutics
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Charts implemented using Lightweight Charts™